A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS)
Mark E McClure,
Seerapani Gopaluni,
James Wason,
Robert B Henderson,
Andre van Maurik,
Caroline C O Savage,
Charles D Pusey,
Alan D Salama,
Paul A Lyons,
Jacinta Lee,
Kim Mynard,
David R Jayne,
Rachel B Jones
Apr 11, 2023
Background
Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several...